Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Organic Chemicals
Clear Filters

Search Clinical Trials

31 Results
Terminated
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
For patients with stage IIIB/IV non-small cell lung cancer, who did not progress after first line chemotherapy, lenalidomide 10mg/day orally will be administered as maintenance therapy until disease progression or …
Baylor Role: Collaborator
Unknown Status
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER
Current treatment of neurogenic bladder dysfunction (NGB) is limited by the suboptimal results achieved using standard antimuscarinic agents. A prominent role for the actions of alternative transmitters/growth factors in peripheral …
Terminated
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Previously, some of the cancer cells were taken from the subject's body and separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum …
Baylor Role: Collaborator
Withdrawn
Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension
The purpose of the study is to find out if taking a dose of gabapentin 600 mg by mouth (po) before surgery will help prevent the development of tourniquet pain …
Baylor Role: Lead Sponsor
Completed
Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study
Subjects were randomized to one of two groups (group A or B). Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator
Completed
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
With the exception of patients with diffuse intrinsic pontine glioma (DIPG), all patients should have the maximal surgical resection that can be safely performed prior to study entry. Submission of …
Baylor Role: Lead Sponsor
Completed
Rivastigmine as a Treatment for Methamphetamine Dependence
We recently completed a double-blind placebo-controlled human laboratory study demonstrating that treatment with a low dose of the acetylcholinesterase (AChE) inhibitor rivastigmine reduced methamphetamine (METH)-induced craving (see Preliminary Studies, Fig. …
Baylor Role: Lead Sponsor
Completed
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
The purpose of this study is to evaluate the interactions between cocaine and oral rivastigmine and between cocaine and oral huperzine A (HupA). The following Specific Aims are proposed: 1. …
Baylor Role: Lead Sponsor